Meeting
2022 ASCO Annual Meeting
Phase 3 randomized study comparing docetaxel-platinum with docetaxel-platinum-5 fluorouracil as neoadjuvant chemotherapy in technically unresectable oral cancer.
Authors
Ajaykumar Singh
Tata Memorial Centre, Mumbai, India
Ajaykumar Singh , Vijay Maruti Patil , Vanita Noronha , Nandini Sharrel Menon , Pankaj Chaturvedi , Vijayalakshmi Mathrudev , Atanu Bhattacharjee , Sunil Ramdhan Chopade , Sujay Srinivas , Somnath Roy , Tanmoy Mondal , Hollis D'souza , Devendra A Chaukar , P. S. Pai , Sudhir Vasudevan Nair , Shivakumar Thiagarajan , Sarbani Laskar , Kavita Prakash Nawale , Sachin Babanrao Dhumal , Kumar Prabhash
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
CTRI/2016/04/006804
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6013)
DOI
10.1200/JCO.2022.40.16_suppl.6013
Abstract #
6013
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Docetaxel-based triplet neoadjuvant therapy for esophageal adenocarcinoma: A comprehensive analysis of outcomes spanning over a decade.
First Author: James Tankel
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized phase III study comparing 2-weekly docetaxel, cisplatin and 5-FU (bDCF) with cisplatin and 5-FU (CF) in patients with metastatic or recurrent esophageal cancer: JCOG1314 (MIRACLE).
First Author: Takahiro Tsushima
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized controlled phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced esophageal cancer with no pathological complete response: JCOG2206 (SUNRISE Trial).
First Author: Satoru Matsuda
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama